Ann: Appendix 4E and Annual Report, page-10

Financial Performance:

1. Revenue and Profit/Loss:

   • Net Loss: The company reported a significant increase in spending from ordinary activities after tax, which is up 295% to $149,680,539 for the year ended 30 June 2024. This is a substantial increase compared to the previous year.

2. Net Tangible Assets:

   • Per Security: The net tangible assets per security decreased from 2.74 cents in 2023 to 1.15 cents in 2024.

Operational Highlights:

1. Pipeline Progress:

   • Imugene made significant advancements across its oncology assets, including Phase 1 and Phase 1b trials for its key products such as Azer-cel, VAXINIA, and onCARlytics.
   • Azer-cel: Progress in Phase 1b trials for Diffuse Large B Cell Lymphoma (DLBCL) patients. This therapy is notable for its potential to be the first approved allogeneic CAR T cell therapy.
   • VAXINIA: Early positive signals in Phase 1 trials for solid tumors, receiving FDA Fast Track Designation for bile duct cancer.
   • onCARlytics: Initiation of Phase 1 trials combining oncolytic virotherapy with other treatments for advanced solid tumors.

2. Strategic Moves:

   • Acquisition of the Azer-cel allogeneic CD19 CAR T cell therapy program from Precision Biosciences, Inc.
   • Partnership with Kincell Bio for the sale of a manufacturing facility, expected to save significant operational costs.

3. Financial Position:

   • Cash Reserves: Reduced from $153,150,662 in 2023 to $93,107,538 in 2024, reflecting increased spending on R&D and acquisitions.
   • Capital Raise: Successfully raised $35 million through a placement and an additional $18.2 million via a Share Purchase Plan (SPP).

4. Management and Corporate Changes:

   • Strengthened senior management team with new appointments, including Chief Operating Officer and Chief Medical Officer.